Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other ...
Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
Novo Nordisk (NVO) has released an update. Novo Nordisk has disclosed recent transactions involving the purchase of 1,300 American Depositary Receipts (ADRs) by its board members and executives. This ...
Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...
Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated ...
It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
Novo Nordisk Fonden tjener ikke kun milliarder på vægttabs- og diabetesmedicin ved at eje Novo Nordisk. Fonden ejer også en af verdens største leverandører af ingredienser til den globale ...
The Danish drug company Novo Nordisk has been sanctioned by the UK pharmaceutical industry regulator over the way it has promoted its weight loss medications semaglutide (Ozempic/Wegovy) and ...
This marks Novo Nordisk's second win this year in treating cardiovascular disease. The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic ...
Danskere med type 2-diabetes eller svær overvægt vil fra næste uge få af et alternativ til de i forvejen kendte diabetes- og vægttabsmidler Ozempic og Wegovy fra danske Novo Nordisk. Det sker, når det ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback